Pharma BD Deal Intelligence
Kaken Pharmaceutical Co., Ltd. / KalVista Pharmaceuticals, Inc.
2025 · Licensing/Option · $24M · Complete
KalVista Pharmaceuticals, through its wholly-owned subsidiary KalVista Pharmaceuticals Ltd., entered a License, Supply and Distribution Agreement granting Kaken Pharmaceutical exclusive commercialization rights in Japan to sebetralstat, an investigational oral on-demand treatment for hereditary angioedema. KalVista receives an $11 million upfront payment within 30 days and up to approximately $13 million in additional regulatory and sales milestones, plus effective royalties in the mid-twenties percent of the Japanese NHI price.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Apr 08, 2025
- Deal value $24M
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Kaken Pharmaceutical Co., Ltd. deals